×

Therapeutic methods employing sialylated glycoforms of soluble complement receptor 1 (SCR 1)

  • US 5,858,969 A
  • Filed: 06/06/1995
  • Issued: 01/12/1999
  • Est. Priority Date: 08/07/1992
  • Status: Expired due to Term
First Claim
Patent Images

1. A method of treating a disease or disorder associated with inflammation or inappropriate complement activation comprising administering to a subject in need of such treatment a pharmaceutical composition comprising a pharmaceutically acceptable carrier or excipient and a therapeutically effective amount of sCR1 glycoprotein molecules, in which said composition exhibits dominant isoforms of sCR1 glycoprotein molecules which have an isoelectric point, pI, less than or equal to 5.1 as determined by chromatofocusing, and wherein the pI of said dominant isoforms increases after neuraminidase treatment.

View all claims
  • 5 Assignments
Timeline View
Assignment View
    ×
    ×